SCEMBLIX Peers Answer FAQs

Real patients, real answers

Only another person living with Ph+ CML in chronic phase can know what it’s like to walk in your shoes. That’s the idea behind SCEMBLIX Peers—actual patients who share their personal experience to answer frequently asked questions (FAQs) in a series of short videos.

Choose your SCEMBLIX Peer

Choose the SCEMBLIX Peer whose experience seems most similar to yours. Please note, SCEMBLIX Peers cannot provide clinical advice or counseling. For medical questions, speak with your doctor.

Lynne’s struggles with side effects

Lynne was diagnosed with Ph+ CML in chronic phase in 2005. Unmanageable side effects led Lynne’s doctor to switch her to different tyrosine kinase inhibitors (TKIs) over the years. Based on her struggles with side effects, Lynne joined the clinical trials for SCEMBLIX in 2015 and has been on treatment ever since.

 

Al’s experience with multiple TKIs

Having been diagnosed in 1997, Al has a long-term perspective on Ph+ CML in chronic phase and has been prescribed several TKIs. Al joined the clinical trials for SCEMBLIX in 2016 after experiencing a lack of response on other medications and continues to take SCEMBLIX.

 

Individual results may vary.

 

SCEMBLIX Peers are actual patients who have been compensated by Novartis Pharmaceuticals Corporation.